NCE Discovery and Domainex merge to create a new drug discovery company
The new company combines NCED's expertise in medicinal chemistry with Domainex's innovative Combinatorial Domain Hunting (CDH) technique for producing recombinant proteins, forming a well-rounded platform for novel drug discovery. Domainex will apply this powerful combination of structural biology and medicinal chemistry approaches to the development of small-molecule drugs with activity against key NTP-dependent protein targets.
Both NCE Discovery and Domainex are spinout companies from University College London (UCL) which, via UCL Cruciform Ltd, is a major shareholder of NCE Discovery and holds shares directly in Domainex. Domainex is also a spinout of the Institute of Cancer Research and Birkbeck College London. UCL Business plc (UCLB), a wholly owned subsidiary of UCL, has also become an investor in the new merged company.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.